Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | HAAO | P46952 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130116 | 0.88 | CYP1A2 (0.46) | CYP1A2HAAOALDH1A1KDM4EHSD17B10 | |
| SCHEMBL2898402 | 0.84 | HAAO (0.42) | CYP1A2HAAOALDH1A1KDM4EHSD17B10 | |
| SCHEMBL2649706 | 0.83 | CSNK2A1 (0.48) | CYP1A2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL28739998 | 0.83 | HAAO (0.41) | CYP1A2HAAOALDH1A1KDM4EHSD17B10 | |
| SCHEMBL28090437 | 0.83 | CYP1A2 (0.41) | CYP1A2HAAOALDH1A1KDM4EHSD17B10 | |
| SCHEMBL242262 | 0.81 | CYP1A2 (0.48) | CYP1A2HAAOALDH1A1KDM4EHSD17B10 | |
| SCHEMBL29370019 | 0.81 | CYP1A2 (0.48) | CYP1A2HAAOALDH1A1KDM4EHSD17B10 | |
| SCHEMBL28033212 | 0.81 | CYP1A2 (0.48) | CYP1A2HAAOALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31636330 | 0.81 | ALDH1A1 (0.44) | CYP1A2ALDH1A1KDM4EHPGDNOTUM | |
| SCHEMBL128319 | 0.80 | CYP1A2 (0.58) | CYP1A2HAAOALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170868-B | Synthetic method of 2, 4-dimethyl-3-methylsulfonylbenzoic acid | 北京印刷学院 | 2022-07-12 | — | — | CN | claimed |
| CN-111170868-A | Synthetic method of 2, 4-dimethyl-3-methylsulfonylbenzoic acid | 北京印刷学院 | 2020-05-19 | — | — | CN | claimed |
| CN-111170868-B | Synthetic method of 2, 4-dimethyl-3-methylsulfonylbenzoic acid | 北京印刷学院 | 2022-07-12 | — | — | CN | disclosed |
| EP-3083583-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | SAGIMET BIOSCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| CN-111170868-A | Synthetic method of 2, 4-dimethyl-3-methylsulfonylbenzoic acid | 北京印刷学院 | 2020-05-19 | — | — | CN | disclosed |
| EP-2870150-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3 V BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | 3-V BIOSCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10118913-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-10053450-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20160338998-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | 3-V BIOSCIENCES, INC. (US) | 2016-11-24 | — | — | US | disclosed |
| EP-2545050-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8293909-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-13 | — | — | US | disclosed |
| US-8198449-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| WO-2011112186-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-2331502-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| WO-2010030538-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10118913-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | CYP1A2 302/4885HAAO 929/4885ALDH1A1 879/4885 |
| US-10053450-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | CYP1A2 302/4885HAAO 929/4885ALDH1A1 879/4885 |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | CYP1A2 302/4885HAAO 929/4885ALDH1A1 879/4885 |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP1A2 386/4885HAAO 2925/4885ALDH1A1 447/4885 |
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | FASN, FADS1, COASY | CYP1A2 308/4885HAAO 1121/4885ALDH1A1 959/4885 |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP1A2 386/4885HAAO 2925/4885ALDH1A1 447/4885 |
| US-20160338998-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | FASN, FADS1, COASY | CYP1A2 308/4885HAAO 1121/4885ALDH1A1 959/4885 |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP1A2 386/4885HAAO 2925/4885ALDH1A1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.